Welcome to our dedicated page for Neoleukin Therapeutics news (Ticker: NLTX), a resource for investors and traders seeking the latest updates and insights on Neoleukin Therapeutics stock.
Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical innovator developing next-generation immunotherapies through advanced protein design. This hub provides essential updates on corporate developments and research milestones for investors tracking this Nasdaq-listed company.
Access authoritative reports on key financial actions including the 2023 reverse stock split and operational restructuring designed to optimize capital allocation. Stay informed about strategic initiatives like the proposed merger and its implications for shareholder value.
Our curated news collection features verified updates on:
• Therapeutic pipeline advancements
• Corporate governance decisions
• Financial strategy implementations
• Partnership and merger developments
For direct inquiries, consult Neoleukin's official website or contact investor relations at investors@neoleukin.com. Bookmark this page for real-time updates on NLTX's progress in redefining immunotherapy treatments.
Neoleukin Therapeutics (NASDAQ: NLTX) has appointed Holly K. Vance as General Counsel. Ms. Vance previously served as Associate General Counsel at the Bill & Melinda Gates Foundation, focusing on life sciences investments. She has extensive legal experience from her time at K&L Gates LLP in corporate and securities law. CEO Jonathan Drachman expressed enthusiasm for Vance's leadership and expertise, which are expected to enhance Neoleukin's strategic initiatives during a pivotal time for the company. Vance holds multiple degrees from the University of Washington.
Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) appointed Martin Babler to its Board of Directors, bringing extensive biopharmaceutical experience. Previously CEO of Principia Biopharma, Babler played a crucial role in its $3.7 billion acquisition by Sanofi. His expertise in commercial development and protein therapeutics is expected to enhance Neoleukin's clinical initiatives, especially in de novo protein design. Babler's background includes leadership positions at Genentech and Eli Lilly, positioning him to contribute significantly as Neoleukin advances its lead candidate, NL-201, aimed at improving treatment for cancer and autoimmune diseases.
Neoleukin Therapeutics, a biopharmaceutical company listed on NASDAQ as NLTX, announced that its CEO, Jonathan Drachman, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 9:30 a.m. Eastern Time. A live audio webcast of the presentation will be available on Neoleukin's investor website, with an archived replay accessible for at least 30 days after the event. Neoleukin focuses on developing next-generation immunotherapies for cancer and other conditions using advanced protein design technology.
Neoleukin Therapeutics (NASDAQ: NLTX) reported a net loss of $9.7 million for Q2 2020 compared to breakeven in Q2 2019, largely due to increased R&D expenses related to its lead candidate NL-201. The company completed a follow-on offering raising $71.4 million to support its clinical plans. NL-201, an IL-2 and IL-15 agonist, is set for IND submission in Q4 2020. Preclinical data shows NL-201 effectively stimulates cancer-fighting cells, with potential benefits across various cancers. Neoleukin's cash position stood at $129.6 million as of June 30, 2020, expected to fund operations through 2023.
Neoleukin Therapeutics (NASDAQ: NLTX) announced participation in a fireside chat at the Canaccord Genuity 40th Annual Growth Conference on August 13, 2020, at 8:30 a.m. ET. The session will be available via live audio webcast on Neoleukin's investor website, with an archived replay accessible for 30 days post-event. Neoleukin is pioneering next-generation immunotherapies using de novo protein design technology and is developing NL-201, an IL-2 and IL-15 agonist aimed at enhancing tolerability and effectiveness.
Neoleukin Therapeutics (NASDAQ: NLTX) plans to report its second quarter 2020 financial results on August 12, 2020, following the market close. A conference call and webcast will be held at 1:30 p.m. Pacific / 4:30 p.m. Eastern to discuss these results and provide an update on corporate activities. The archived webcast will be available on Neoleukin's website for at least 30 days. Neoleukin focuses on creating next-generation immunotherapies for cancer, inflammation, and autoimmunity using advanced protein design technology.
Neoleukin Therapeutics (NLTX) plans to offer up to 5 million shares of common stock and pre-funded warrants in an underwritten public offering, with an additional 750,000 shares available underwriters’ option. The net proceeds will be directed towards advancing the development of NL-201, expanding protein design technology, preclinical pipeline efforts, and general corporate purposes. BofA Securities, Piper Sandler, and Guggenheim Securities are managing the offering. This announcement comes amid ongoing market uncertainties.
Neoleukin Therapeutics (NASDAQ: NLTX) presented promising preclinical data on its lead immunotherapy candidate, NL-201, at the AACR Virtual Annual Meeting II. The data highlights NL-201’s ability to stimulate and expand CD8 T cells and NK cells, demonstrating durable anti-tumor activity across various tumor types. Notably, NL-201 showed minimal immunogenicity and was well-tolerated in non-human primates. The company plans to advance NL-201 into clinical trials, with IND-enabling activities on track for submission by the end of 2020. Neoleukin will host an Investor R&D Showcase on June 23.
Neoleukin Therapeutics (NASDAQ: NLTX) announced the appointment of Erin Lavelle to its Board of Directors, bringing over 20 years of biopharmaceutical experience. Lavelle, previously COO of Alder Biopharmaceuticals, will succeed Sean Nolan, who stepped down after years of service. CEO Jonathan Drachman praised Lavelle's operational expertise as vital for advancing their de novo protein design technology and preparing for upcoming clinical trials. Neoleukin focuses on innovative immunotherapies using computational methods for better therapeutic outcomes.
